Document is current

Article History

Received: 17 May 2023

Accepted: 6 March 2024

First Online: 2 April 2024

Declarations

:

: This study was conducted in accordance with the declaration of Helsinki. Approval with a waiver for informed consent was granted by the local ethics committee (Comité Ética de la Investigación, Hospital Universitario Nacional de Colombia, project ID: CEI-2020-07-02).

: Not applicable.

: S.C-R. has received in the past three years travel expenses for scientific meetings from Roche, Merck, and Genzyme; compensation for consulting services or participation on advisory boards from Merck, Biogen-Idec, Sanofi and Novartis; lecture fees from Novartis, Merck, Sanofi, Janssen and Biogen-Idec; and research support from Biogen-Idec and Novartis. He is a subject editor on Multiple Sclerosis for Acta Neurológica Colombiana and a member of the editorial board of Frontiers of Neurology. L.E.A-V. has received travel expenses for scientific meetings from Biogen and Roche. R.D.A., J.M.G-T., A.M.M-R., A.H.T-B., D.S.M-M. declare no competing interests. H.A.A-F. has received travel expenses for scientific meetings from Roche. C.G-S. reports consulting fees from Novartis, Biogen-Idec, Merck, Roche and Sanofi-Genzyme; and travel expenses for scientific meetings from Sanofi-Genzyme and Roche. L.L-R. reports consulting fees from Roche and Merck; and travel expenses for scientific meetings from Tecnofarma and Biogen.